JPRN-UMIN000006294已完成未知
Efficacy of Nilotinib in Patients with Chronic Myeloid Leukemia in chronic phase unachieved Complete Molecular Response - Efficacy of Nilotinib in Patients with CML unachieved CMR
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients suspected in AP and BC 2) Pregnant and/or lactating woman 3) Severe psychological disorders 4) Uncontorlled complications
研究者
相似试验
已完成
2 期
Study of Nilotinib usefulness for chronic myeloid leukemia (CML) patients with Imatinib resistant or intolerant.Chronic myeloid leukemiaJPRN-UMIN000003016Osaka CML-MRD Meeting45
进行中（未招募）
1 期
Treatment for patients whith graft-versus-host disease after bone marrow transplantation.Chronic graft-versus-host disease .MedDRA version: 14.1Level: LLTClassification code 10008907Term: Chronic GVH diseaseSystem Organ Class: 100000004870EUCTR2012-000770-36-BECHU-ULg5
尚未招募
不适用
To stop the use of Imatinib in CML-CP patientsCTRI/2019/07/020407DR BRA IRCH AIIMS
已完成
2 期
Effect of Imatinib Mesylate in patients undergone allogeneic bone marrow transplantation who show chronic coetaneous involvement Graft Versus-Host Disease.cutaneous cGVHD.Graft-versus-host reaction or diseaseIRCT201302261030N12Hematology-Oncology and SCT Research Center28
已完成
2 期
Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.Philadelphia Positive (Ph+) Chronic Myelogenous LeukemiaNCT01844765Novartis Pharmaceuticals59